A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Нема приказа
Аутори
Rizzo, ManfrediRizvi, Ali A.
Sudar, Emina
Soskić, Sanja S.
Obradović, Milan M.
Montalto, Giuseppe
Boutjdir, Mohamed
Mikhailidis, Dimitri P.
Isenović, Esma R.
Приказ
Метаподаци
Приказ свих података о документуАпстракт
Ghrelin is a peptide hormone produced mainly in the stomach that has widespread tissue distribution and diverse hormonal, metabolic and cardiovascular activities. The circulating ghrelin concentration increases during fasting and decreases after food intake. Ghrelin secretion may thus be initiated by food intake and is possibly controlled by nutritional factors. Lean subjects have increased levels of circulating ghrelin compared with obese subjects. Recent reports show that low plasma ghrelin is associated with elevated fasting insulin levels, insulin resistance and type 2 diabetes mellitus. Factors involved in the regulation of ghrelin secretion have not yet been defined; however, it is assumed that blood glucose levels represent a significant regulator. Recent evidence indicates that ghrelin can increase myocardial contractility, enhance vasodilatation, and has protective effect from myocardial damage. It has been shown that ghrelin may improve cardiac function through growth hormone... (GH)-dependent mechanisms but there is also evidence to suggest that ghrelins cardioprotective activity is independent of GH. Recent data demonstrate that ghrelin can influence key events in atherogenesis. Thus, ghrelin may be a new target for the treatment of some cardiovascular diseases. In this review, we consider the current literature focusing on ghrelin as a potential antiatherogenic agent in the treatment of various pathophysiological conditions.
Кључне речи:
Ghrelin / cardiovascular system / cardiovascular diseases / atherosclerosis / type 2 diabetes mellitusИзвор:
Current Pharmaceutical Design, 2013, 19, 27, 4953-4963Финансирање / пројекти:
- Хормонска регулација експресије и активности азот оксид синтазе и натријум-калијумове пумпе у експерименталним моделима инсулинске резистенције, дијабетеса и кардиоваскуларних поремећаја (RS-MESTD-Basic Research (BR or ON)-173033)
DOI: 10.2174/1381612811319270018
ISSN: 1381-6128; 1873-4286
PubMed: 23278489
WoS: 000321045100018
Scopus: 2-s2.0-84881348966
Колекције
Институција/група
VinčaTY - JOUR AU - Rizzo, Manfredi AU - Rizvi, Ali A. AU - Sudar, Emina AU - Soskić, Sanja S. AU - Obradović, Milan M. AU - Montalto, Giuseppe AU - Boutjdir, Mohamed AU - Mikhailidis, Dimitri P. AU - Isenović, Esma R. PY - 2013 UR - https://vinar.vin.bg.ac.rs/handle/123456789/5565 AB - Ghrelin is a peptide hormone produced mainly in the stomach that has widespread tissue distribution and diverse hormonal, metabolic and cardiovascular activities. The circulating ghrelin concentration increases during fasting and decreases after food intake. Ghrelin secretion may thus be initiated by food intake and is possibly controlled by nutritional factors. Lean subjects have increased levels of circulating ghrelin compared with obese subjects. Recent reports show that low plasma ghrelin is associated with elevated fasting insulin levels, insulin resistance and type 2 diabetes mellitus. Factors involved in the regulation of ghrelin secretion have not yet been defined; however, it is assumed that blood glucose levels represent a significant regulator. Recent evidence indicates that ghrelin can increase myocardial contractility, enhance vasodilatation, and has protective effect from myocardial damage. It has been shown that ghrelin may improve cardiac function through growth hormone (GH)-dependent mechanisms but there is also evidence to suggest that ghrelins cardioprotective activity is independent of GH. Recent data demonstrate that ghrelin can influence key events in atherogenesis. Thus, ghrelin may be a new target for the treatment of some cardiovascular diseases. In this review, we consider the current literature focusing on ghrelin as a potential antiatherogenic agent in the treatment of various pathophysiological conditions. T2 - Current Pharmaceutical Design T1 - A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin VL - 19 IS - 27 SP - 4953 EP - 4963 DO - 10.2174/1381612811319270018 ER -
@article{ author = "Rizzo, Manfredi and Rizvi, Ali A. and Sudar, Emina and Soskić, Sanja S. and Obradović, Milan M. and Montalto, Giuseppe and Boutjdir, Mohamed and Mikhailidis, Dimitri P. and Isenović, Esma R.", year = "2013", abstract = "Ghrelin is a peptide hormone produced mainly in the stomach that has widespread tissue distribution and diverse hormonal, metabolic and cardiovascular activities. The circulating ghrelin concentration increases during fasting and decreases after food intake. Ghrelin secretion may thus be initiated by food intake and is possibly controlled by nutritional factors. Lean subjects have increased levels of circulating ghrelin compared with obese subjects. Recent reports show that low plasma ghrelin is associated with elevated fasting insulin levels, insulin resistance and type 2 diabetes mellitus. Factors involved in the regulation of ghrelin secretion have not yet been defined; however, it is assumed that blood glucose levels represent a significant regulator. Recent evidence indicates that ghrelin can increase myocardial contractility, enhance vasodilatation, and has protective effect from myocardial damage. It has been shown that ghrelin may improve cardiac function through growth hormone (GH)-dependent mechanisms but there is also evidence to suggest that ghrelins cardioprotective activity is independent of GH. Recent data demonstrate that ghrelin can influence key events in atherogenesis. Thus, ghrelin may be a new target for the treatment of some cardiovascular diseases. In this review, we consider the current literature focusing on ghrelin as a potential antiatherogenic agent in the treatment of various pathophysiological conditions.", journal = "Current Pharmaceutical Design", title = "A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin", volume = "19", number = "27", pages = "4953-4963", doi = "10.2174/1381612811319270018" }
Rizzo, M., Rizvi, A. A., Sudar, E., Soskić, S. S., Obradović, M. M., Montalto, G., Boutjdir, M., Mikhailidis, D. P.,& Isenović, E. R.. (2013). A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin. in Current Pharmaceutical Design, 19(27), 4953-4963. https://doi.org/10.2174/1381612811319270018
Rizzo M, Rizvi AA, Sudar E, Soskić SS, Obradović MM, Montalto G, Boutjdir M, Mikhailidis DP, Isenović ER. A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin. in Current Pharmaceutical Design. 2013;19(27):4953-4963. doi:10.2174/1381612811319270018 .
Rizzo, Manfredi, Rizvi, Ali A., Sudar, Emina, Soskić, Sanja S., Obradović, Milan M., Montalto, Giuseppe, Boutjdir, Mohamed, Mikhailidis, Dimitri P., Isenović, Esma R., "A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin" in Current Pharmaceutical Design, 19, no. 27 (2013):4953-4963, https://doi.org/10.2174/1381612811319270018 . .